Lyra Therapeutics, Inc. has announced a definitive agreement to sell 423,372 shares of common stock and associated private placement warrants through a registered direct offering priced at $11.81 per ...
LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results